Log In
BCIQ
Print this Print this
 

MSC_Apceth

  Manage Alerts
Collapse Summary General Information
Company apceth GmbH & Co. KG
DescriptionHuman autologous CD34-negative, bone-marrow derived mesenchymal stem cells
Molecular Target
Mechanism of Action 
Therapeutic ModalityCell therapy: Stem cell
Latest Stage of DevelopmentPhase I/II
Standard IndicationIschemia / reperfusion injury
Indication DetailsTreat critical limb ischemia (CLI) in patients with advanced peripheral arterial occlusive disease (pAOD) after angioplasty
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today